CTMXCytomX Therapeutics, Inc.

$846M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M-36.6% YoY

Gross Profit

$10M86.7% margin

Operating Income

-$30M-266.5% margin

Net Income

-$29M-260.7% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

-13.3%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$34M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$226M

Total Liabilities

$198M

Stockholders' Equity

$28M

Cash & Equivalents

$95M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$18M	-36.6%
Gross Profit	$10M	$18M	-45.1%
Operating Income	-$30M	-$23M	-31.2%
Net Income	-$29M	-$23M	-28.7%

CTMX Q3 2022 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena